The 2nd Healthcare Innovation Forum with the theme "Innovative approaches to improve healthcare in Vietnam" was organized by Pharma Group today, October 18, in Hanoi and connected online with international experts.
At the forum, managers and researchers in the medical and pharmaceutical fields discussed experiences, research trends, inventions, and practical contributions to realize the development goals of the Vietnamese medical and pharmaceutical industry.
At the forum, speakers recommended digital transformation and application of information technology to help Vietnamese healthcare develop more strongly and increase opportunities to receive new pharmaceutical technology.
Mr. Emin Turan, Chairman of Pharma Group, shared that with available potential and by filtering international experiences, Vietnam can completely aim to improve healthcare and become a center of science and innovation in the region.
As the demand for healthcare in Vietnam continues to grow, innovation in the healthcare sector plays a vital role in improving the quality of healthcare, enhancing the ability to diagnose and treat diseases, and promoting progress in medical research.
In addition, advanced technologies such as artificial intelligence, data analysis, virtual reality, blockchain and robotics have been widely applied in healthcare to save time, costs, and improve the quality of life and human health.
The Chairman of Pharma Group especially appreciated the National Strategy for the Development of the Vietnamese Pharmaceutical Industry to 2023, with a vision to 2045 approved by the Government, saying that the issued and revised policies will increase access to new drugs and treatment methods in healthcare in Vietnam.
New faster approval process could expand clinical trials
Sharing more about clinical trials and opportunities to access new drugs and treatment methods, Associate Professor - Dr. Dao Van Tu, Director of the Clinical Trials Center (Central Cancer Hospital), said that clinical trials play an important role in applying research results to humans.
Through his 15 years of professional experience working with cancer patients, Dr. Dao Van Tu shared that about 5-6 years ago, many patients and many doctors thought that those participating in clinical trials were "lab rats". But this misunderstanding has changed.
In Vietnam, clinical trials are currently only conducted with products that are qualified for human use, and are not considered dangerous research. Participating in clinical research is an opportunity to access new treatment methods; in fact, there have been cancer patients who have been treated and have gone into remission after participating in the research.
Dr. Tu also shared that clinical trials in cancer treatment are increasing rapidly in many countries, but in Vietnam there are still some limitations. The reason is that the rate of patients participating in clinical trials in Vietnam is currently only 1-2%, while in many countries, this rate is at least 10%.
Domestic units still lack human resources to carry out clinical trials. In addition, the domestic approval process must be faster so that clinical trials in Vietnam can be expanded.
According to the Ministry of Health, Vietnam is focusing on improving its research capacity and applying available technology to produce generic drugs and drugs with new and modern dosage forms, aiming to become a center for manufacturing and receiving technology transfer of generic drugs in the ASEAN region.
Strive to develop the domestic pharmaceutical industry to level 4 - the highest level, according to the classification of the World Health Organization. By 2030, 100% of drugs will be proactively and promptly supplied for disease prevention and treatment needs; ensure drug security, meet the requirements of national defense, security, disease prevention and control, overcome the consequences of natural disasters, catastrophes, public health incidents and other urgent drug needs.
Domestically produced drugs strive to meet about 80% of usage demand and 70% of market value; continue to strive to achieve the goal of producing 20% of raw material demand for domestic drug production...
Source link
Comment (0)